Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Affimed to host virtual investor meeting » 16:34
12/08/21
12/08
16:34
12/08/21
16:34
AFMD

Affimed

$6.82 /

+0.38 (+5.90%)

Virtual Investor Meeting…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AFMD Affimed
$6.82 /

+0.38 (+5.90%)

AFMD Affimed
$6.82 /

+0.38 (+5.90%)

11/17/21 Berenberg
Affimed initiated with a Buy at Berenberg
10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
AFMD Affimed
$6.82 /

+0.38 (+5.90%)

  • 13
    Jan
AFMD Affimed
$6.82 /

+0.38 (+5.90%)

Hot Stocks
Affimed begins enrollment for Phase 1/2a trial of AM24 with Roche's atezolizumab » 06:40
12/08/21
12/08
06:40
12/08/21
06:40
AFMD

Affimed

$6.44 /

+0.34 (+5.57%)

, RHHBY

Roche

$49.77 /

+0.04 (+0.08%)

Affimed (AFMD) initiated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$49.77 /

+0.04 (+0.08%)

AFMD Affimed
$6.44 /

+0.34 (+5.57%)

AFMD Affimed
$6.44 /

+0.34 (+5.57%)

11/17/21 Berenberg
Affimed initiated with a Buy at Berenberg
10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
RHHBY Roche
$49.77 /

+0.04 (+0.08%)

12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
RHHBY Roche
$49.77 /

+0.04 (+0.08%)

AFMD Affimed
$6.44 /

+0.34 (+5.57%)

  • 13
    Jan
RHHBY Roche
$49.77 /

+0.04 (+0.08%)

RHHBY Roche
$49.77 /

+0.04 (+0.08%)

AFMD Affimed
$6.44 /

+0.34 (+5.57%)

Over a week ago
Hot Stocks
Affimed reports interim results from Phase 1-2 study of cbNK cells, AFM13 » 07:26
11/22/21
11/22
07:26
11/22/21
07:26
AFMD

Affimed

$6.73 /

-0.08 (-1.18%)

Affimed announced interim…

Affimed announced interim clinical results from the investigator-initiated phase 1-2 study at The University of Texas MD Anderson Cancer Center, evaluating cbNK cells pre-complexed with Affimed's innate cell engager, ICE, AFM13. As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas were treated with the novel combination of cbNK cells pre-complexed with AFM13. A treatment cycle consists of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed two days later by a single infusion of cytokine-preactivated and expanded cbNK cells that are pre-complexed with AFM13, followed by three weekly infusions of AFM13 monotherapy. Responses are assessed on day 28 by FDG-PET and patients can receive up to two cycles. Three patients were treated with 1x106, three patients with 1x107 and 12 patients with 1x108 AFM13-pre-complexed cbNK cells per kg body weight. As of the cutoff date, 16 of 18 patients had achieved an objective response to the treatment according to investigator assessment, with seven complete responses, CR, and nine partial responses, PR. Eleven of twelve patients treated at the recommended phase 2 dose level of 108 cbNK cells per kg had Hodgkin Lymphoma. In this cohort of patients treated at the recommended phase 2 dose, 100% responded after the first cycle of treatment with five CRs and seven PRs according to investigator assessment. Treatment was well tolerated with five reported cases of transient infusion related reactions after the monotherapy infusions of AFM13. Of note, there were no instances of serious adverse events such as cytokine release syndrome, immune cell-associated neurotoxicity syndrome or graft-versus-host disease.

ShowHide Related Items >><<
AFMD Affimed
$6.73 /

-0.08 (-1.18%)

AFMD Affimed
$6.73 /

-0.08 (-1.18%)

11/17/21 Berenberg
Affimed initiated with a Buy at Berenberg
10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
AFMD Affimed
$6.73 /

-0.08 (-1.18%)

  • 13
    Jan
AFMD Affimed
$6.73 /

-0.08 (-1.18%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/21
11/18
04:55
11/18/21
04:55
ALXO

ALX Oncology

$42.93 /

-2.02 (-4.49%)

, GLTO

Galecto

$3.05 /

-0.13 (-4.09%)

, NBTX

Nanobiotix

$9.35 /

-0.2 (-2.09%)

, EXAS

Exact Sciences

$88.36 /

-3.12 (-3.41%)

, RXDX

Prometheus

$38.32 /

+2.32 (+6.44%)

, ARWR

Arrowhead

$63.75 /

-0.07 (-0.11%)

, PNT

Point Biopharma

$8.90 /

-0.13 (-1.44%)

, CNCE

Concert Pharmaceuticals

$3.99 /

-0.08 (-1.97%)

, AFMD

Affimed

$6.73 /

+0.605 (+9.88%)

, EPIX

Essa Pharma

$13.00 /

-0.31 (-2.33%)

, GRTX

Galera Therapeutics

$1.69 /

+0.015 (+0.90%)

, INAB

In8bio

$8.05 /

+ (+0.00%)

, KROS

Keros Therapeutics

$60.31 /

-2.51 (-4.00%)

, LABP

Landos Biopharma

$10.17 /

-0.55 (-5.13%)

, SVRA

Savara

$1.12 /

-0.005 (-0.45%)

, STRO

Sutro Biopharma

$18.47 /

-0.57 (-2.99%)

, VACC

Vaccitech

$12.70 /

+0.01 (+0.08%)

, ZNTL

Zentalis

$79.38 /

+2.39 (+3.10%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

INAB In8bio
$8.05 /

+ (+0.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.05 /

-0.13 (-4.09%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.73 /

+0.605 (+9.88%)

11/17/21 Berenberg
Affimed initiated with a Buy at Berenberg
10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.05 /

+ (+0.00%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.005 (-0.45%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

11/17/21 Berenberg
Sutro Biopharma initiated with a Buy at Berenberg
06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

INAB In8bio
$8.05 /

+ (+0.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

Initiation
Affimed initiated with a Buy at Berenberg » 07:23
11/17/21
11/17
07:23
11/17/21
07:23
AFMD

Affimed

$6.13 /

+0.095 (+1.57%)

Berenberg analyst…

Berenberg analyst Zhiqiang Shu initiated coverage of Affimed with a Buy rating and $11 price target.

ShowHide Related Items >><<
AFMD Affimed
$6.13 /

+0.095 (+1.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
AFMD Affimed
$6.13 /

+0.095 (+1.57%)

  • 13
    Jan
AFMD Affimed
$6.13 /

+0.095 (+1.57%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/17/21
11/17
04:55
11/17/21
04:55
ALXO

ALX Oncology

$45.00 /

-1.185 (-2.57%)

, GLTO

Galecto

$3.18 /

-0.33 (-9.40%)

, NBTX

Nanobiotix

$9.50 /

+ (+0.00%)

, EXAS

Exact Sciences

$91.45 /

+1.56 (+1.74%)

, RXDX

Prometheus

$36.15 /

+1.75 (+5.09%)

, ARWR

Arrowhead

$63.96 /

-1.98 (-3.00%)

, PNT

Point Biopharma

$9.02 /

+0.17 (+1.92%)

, CNCE

Concert Pharmaceuticals

$4.07 /

+0.06 (+1.50%)

, AFMD

Affimed

$6.13 /

+0.095 (+1.57%)

, EPIX

Essa Pharma

$13.37 /

+0.4 (+3.08%)

, GRTX

Galera Therapeutics

$1.68 /

+0.005 (+0.30%)

, INAB

In8bio

$8.05 /

-0.13 (-1.59%)

, KROS

Keros Therapeutics

$62.90 /

+1.4 (+2.28%)

, LABP

Landos Biopharma

$10.65 /

-3.35 (-23.93%)

, SVRA

Savara

$1.12 /

-0.015 (-1.32%)

, STRO

Sutro Biopharma

$19.06 /

-0.04 (-0.21%)

, VACC

Vaccitech

$12.65 /

-0.17 (-1.33%)

, ZNTL

Zentalis

$76.99 /

-0.11 (-0.14%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

INAB In8bio
$8.05 /

-0.13 (-1.59%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.18 /

-0.33 (-9.40%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.50 /

+ (+0.00%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.13 /

+0.095 (+1.57%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.05 /

-0.13 (-1.59%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.015 (-1.32%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

INAB In8bio
$8.05 /

-0.13 (-1.59%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

Conference/Events
Jefferies to hold a virtual conference » 10:32
11/16/21
11/16
10:32
11/16/21
10:32
ALXO

ALX Oncology

$44.59 /

-1.59 (-3.44%)

, GLTO

Galecto

$3.48 /

-0.03 (-0.85%)

, NBTX

Nanobiotix

$9.50 /

+ (+0.00%)

, EXAS

Exact Sciences

$88.17 /

-1.72 (-1.91%)

, RXDX

Prometheus

$34.65 /

+0.25 (+0.73%)

, ARWR

Arrowhead

$64.90 /

-1.04 (-1.58%)

, PNT

Point Biopharma

$8.86 /

+0.01 (+0.11%)

, CNCE

Concert Pharmaceuticals

$3.95 /

-0.06 (-1.50%)

, AFMD

Affimed

$6.03 /

-0.005 (-0.08%)

, EPIX

Essa Pharma

$14.02 /

+1.05 (+8.10%)

, GRTX

Galera Therapeutics

$1.64 /

-0.03 (-1.80%)

, INAB

In8bio

$8.46 /

+0.28 (+3.42%)

, KROS

Keros Therapeutics

$62.28 /

+0.78 (+1.27%)

, LABP

Landos Biopharma

$12.89 /

-1.11 (-7.93%)

, SVRA

Savara

$1.12 /

-0.015 (-1.32%)

, STRO

Sutro Biopharma

$19.16 /

+0.06 (+0.31%)

, VACC

Vaccitech

$12.76 /

-0.06 (-0.47%)

, ZNTL

Zentalis

$77.86 /

+0.755 (+0.98%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

INAB In8bio
$8.46 /

+0.28 (+3.42%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.48 /

-0.03 (-0.85%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.50 /

+ (+0.00%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.03 /

-0.005 (-0.08%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.46 /

+0.28 (+3.42%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.015 (-1.32%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

INAB In8bio
$8.46 /

+0.28 (+3.42%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

Hot Stocks
Affimed announces preclinical data of innate cell engagers at SITC 2021 » 08:30
11/12/21
11/12
08:30
11/12/21
08:30
AFMD

Affimed

$5.87 /

+0.225 (+3.99%)

Affimed announced that…

Affimed announced that three posters with preclinical data of its innate cell engagers are presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, SITC. The data highlight Affimed's preclinical initiatives to further elucidate the mechanisms of action for its lead ICE candidates AFM13 and AFM24, providing evidence that both ICE molecules increased the number of NK cells which functioned as serial killers against cancer as well as the role of macrophages in the anti-tumor activity of AFM24. The poster based on abstract 894 displays data generated through a collaboration with Prof. Bjorn Onfelt's group at the Karolinska Institutet, Stockholm. In the study, microchip technology was used for two ICE drug candidates, AFM13 and AFM24, at single cell resolution to better understand their mode of action. Both ICE molecules enhanced NK cell cytotoxicity and increased the number of serial killers, i.e. NK cells which kill a number of tumor cells sequentially. Shedding inhibition of the innate immune cell surface protein CD16 resulted in the maintained cytotoxic effect of either ICE molecule demonstrating that stabilization of CD16 is not required for effective tumor cell killing by ICE drug candidates. Two additional posters present data on AFM24's ability to induce antibody dependent cellular phagocytosis . AFM24, the bispecific ICE targeting EGFR and CD16A, led to enhanced macrophage-mediated ADCP on various EGFR-expressing tumor cell lines, irrespective of their EGFR-pathway mutational status.

ShowHide Related Items >><<
AFMD Affimed
$5.87 /

+0.225 (+3.99%)

AFMD Affimed
$5.87 /

+0.225 (+3.99%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
AFMD Affimed
$5.87 /

+0.225 (+3.99%)

  • 13
    Jan
AFMD Affimed
$5.87 /

+0.225 (+3.99%)

Syndicate
Affimed files $100M mixed securities shelf  08:13
11/10/21
11/10
08:13
11/10/21
08:13
AFMD

Affimed

$6.23 /

-0.125 (-1.97%)

 
ShowHide Related Items >><<
AFMD Affimed
$6.23 /

-0.125 (-1.97%)

AFMD Affimed
$6.23 /

-0.125 (-1.97%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
AFMD Affimed
$6.23 /

-0.125 (-1.97%)

  • 13
    Jan
AFMD Affimed
$6.23 /

-0.125 (-1.97%)

Earnings
Affimed reports Q3 EPS (14c), consensus (15c) » 06:37
11/10/21
11/10
06:37
11/10/21
06:37
AFMD

Affimed

$6.23 /

-0.125 (-1.97%)

Reports Q3 revenue…

Reports Q3 revenue EUR8.7M vs. EUR10.5M a year ago. Cash and cash equivalents as of September 30, 2021, were approximately EUR198.7M with anticipated cash runway into the second half of 2023. "In the past months, we have significantly expanded our efforts to ensure the development of our leading candidates, AFM13 and AFM24, which we believe will result in multiple catalysts over the next several quarters," said CEO Adi Hoess. "We are excited about AFM28, a ROCK(R) platform-based ICE(R), which we believe will be a novel and promising approach for difficult-to-treat AML patients. We know NK cells have shown some activity in AML and, coupled with what we are seeing in the AFM13 study in combination with NK cells we are hopeful that this highly differentiated product candidate will offer a new treatment option to those patients currently left behind".

ShowHide Related Items >><<
AFMD Affimed
$6.23 /

-0.125 (-1.97%)

AFMD Affimed
$6.23 /

-0.125 (-1.97%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
AFMD Affimed
$6.23 /

-0.125 (-1.97%)

  • 13
    Jan
AFMD Affimed
$6.23 /

-0.125 (-1.97%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.